compounded glp-1 drugs New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these at scale. Our Diabetes advocacy group discourages use

doi: 10.1210/endo.137.7.8770921

GLP-1 drugs have ushered in a new era in weight loss

These medications, originally approved by the FDA for the treatment of Type 2 diabetes, have since been authorized for weight loss therapy and are now recommended by the American Diabetes Association as potential first-line options for both indications

Drugs 79 , 219230 (2019)

In a randomised, placebo-controlled double blinded phase 1 study of ascending single doses in healthy overweight humans, cotadutide was shown to be safe and, in common with the GLP-1 analogues, to be associated with dose-dependent gastrointestinal adverse events especially nausea and vomiting